Tesevatinib ( DrugBank: Tesevatinib )


1 disease
IDDisease name (Link within this page)Number of trials
67Polycystic kidney disease4

67. Polycystic kidney disease


Clinical trials : 221 Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03203642
(ClinicalTrials.gov)
October 12, 201726/6/2017Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKDA Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney;ADPKDDrug: Tesevatinib;Drug: PlaceboKadmon, a Sanofi CompanyNULLCompleted18 Years60 YearsAll80Phase 2United States
2NCT03096080
(ClinicalTrials.gov)
August 24, 20176/3/2017A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)A Phase 1, Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)Polycystic Kidney, Autosomal RecessiveDrug: TesevatinibKadmon Corporation, LLCNULLCompleted5 Years12 YearsAll10Phase 1United States
3NCT02616055
(ClinicalTrials.gov)
December 25, 201524/11/2015Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney Disease (ADPKD)Drug: tesevatinibKadmon Corporation, LLCNULLTerminated18 Years62 YearsAll15Phase 2United States
4NCT01559363
(ClinicalTrials.gov)
December 7, 20129/3/2012A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney DiseaseA Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 ((Tesevatinib) in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)Polycystic Kidney, Autosomal DominantDrug: KD019 (tesevatinib)Kadmon, a Sanofi CompanyNULLCompleted18 Years62 YearsAll74Phase 1/Phase 2United States